Novartis AG (NVS) Latest Company News

Oct 16, 2026, 17:35 UTC
NOVARTIS AG ended a mid-stage trial of Fabhalta targeting a serious kidney condition.
Source:
- reuters.com
Oct 14, 2026, 01:00 UTC
The UK High Court rejected ACCORD HEALTHCARE LIMITED’s challenge to NOVARTIS AG’s supplementary protection certificate for the combination of sacubitril and valsartan.
Source:
- mondaq.com
Oct 10, 2026, 07:19 UTC
NOVARTIS AG, ESR Group Ltd. and Yunsong Asset are jointly investing about 1.8 billion yuan to build the NOVARTIS AG.
Source:
- finance.sina.cn
- finance.sina.cn
Oct 7, 2026, 16:39 UTC
The US Food and Drug Administration expanded the use of a NOVARTIS AG drug to treat adults with a chronic skin condition causing recurring itchy welts.
Source:
- reuters.com
Oct 7, 2026, 16:15 UTC
The U.S. Food and Drug Administration approved NOVARTIS AG’s Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.
Source:
- finanznachrichten.de
- zacks.com
Oct 5, 2026, 17:26 UTC
Novartis acquired global rights to Abogen's ABO2203 in a $7.8 billion deal, strengthening its RNA therapeutics pipeline.
Source:
- zacks.com
Oct 2, 2026, 06:47 UTC
Novartis AG agreed to license an mRNA-based autoimmune therapy from China's Abogen Biosciences in a deal worth up to $7.8 billion.
Source:
Sep 28, 2026, 07:30 UTC
The Kerala High Court ruled that the Central government may invoke Section 100 of the Patents Act to manufacture and sell patented medicines on a non-commercial basis, including when patented drugs are sold at exorbitant prices.
Source:
- livelaw.in
Sep 23, 2026, 23:59 UTC
Novartis's RNA drug del-desiran fell short in a rare muscle disease study.
Source:
- biopharmadive.com
Sep 20, 2026, 23:25 UTC
Telix Pharmaceuticals agreed to acquire all shares of privately held ITM Isotope Technologies Munich SE in a radiopharmaceuticals merger worth at least $1.65 billion, with up to $700 million more contingent on ITM's lead drug meeting regulatory and sales goals.
Source:
Sep 18, 2026, 14:52 UTC
Novartis received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for COSENTYX for the treatment of polymyalgia rheumatica (PMR).
Source:
- finance.sina.cn
- zacks.com
Sep 18, 2026, 03:00 UTC
Nestlé Japan is expanding its nutrition food business for elderly people by broadening distribution beyond medical institutions, mainly to drugstores, and increasing flavor varieties to capture home-care demand.
Source:
- nikkei.com
Sep 17, 2026, 13:30 UTC
Novartis halted development of its investigational ALS therapy VHB937 after the ASTRALS Phase 2 trial failed to meet its primary or secondary endpoints.
Source:
- rttnews.com
Sep 16, 2026, 18:15 UTC
Novartis met with Ghana Medical Trust Fund and expressed willingness to support it with medical equipment, training and research collaboration, with no money committed and no agreement signed.
Source:
- riotimesonline.com
Sep 16, 2026, 12:43 UTC
Novartis announced the termination of development of its ALS drug VHB937.
Source:
- finance.sina.cn
- reuters.com
Sep 15, 2026, 11:30 UTC
Legend Biotech appointed Ingrid Zhang, a Novartis executive, as CEO, ending a nearly two-month search that began when former CEO Ying Huang resigned in July.
Source:
Sep 11, 2026, 13:56 UTC
Novartis shares slumped 11% in one day, wiping nearly $30 billion off its market value, after the failure of the muscle-wasting disorder drug del-desiran in a late-stage study.
Source:
- statnews.com
- seekingalpha.com
Sep 11, 2026, 03:55 UTC
In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.
Source:
- m.21jingji.com
Sep 10, 2026, 21:07 UTC
Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.
Sep 10, 2026, 11:50 UTC
Artisan Partners, a shareholder of Novartis AG, publicly urged the Swiss drugmaker to shake up its board and overhaul its M&A approach after share declines following three clinical trial setbacks.
Source:
Sep 10, 2026, 08:59 UTC
Palantir Technologies hosted its eleventh AIPCon event in Miami, featuring customer presentations on AI applications.
Source:
- businesswire.com
Sep 4, 2026, 21:20 UTC
Ionis Pharmaceuticals and partner Novartis announced on Friday that their experimental heart drug failed in a late-stage trial.
Source:
- reuters.com
Sep 4, 2026, 21:07 UTC
Novartis announced that its experimental cardiovascular drug pelacarsen failed to reduce cardiovascular risk in the Phase 3 HORIZON trial.
Source:
Sep 2, 2026, 12:37 UTC
Novartis plans to cease production at its Kleinhüningen site in Basel, potentially eliminating about 130 jobs, subject to information and consultation procedures.
Source:
Sep 2, 2026, 12:12 UTC
South Korea's Alteogen signed a deal with Swiss drugmaker Novartis worth up to $3.22 billion, granting Novartis access to Alteogen's technology for making injectable versions of intravenous drugs.
Source:
Sep 1, 2026, 07:13 UTC
Novartis announced that its oral drug remibrutinib met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.
Source:
Aug 20, 2026, 10:04 UTC
Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.
Source:
- finance.sina.cn

Page 1Next →

NVS

NOVARTIS AG ended a mid-stage trial of Fabhalta targeting a serious kidney condition.

The UK High Court rejected ACCORD HEALTHCARE LIMITED’s challenge to NOVARTIS AG’s supplementary protection certificate for the combination of sacubitril and valsartan.

NOVARTIS AG, ESR Group Ltd. and Yunsong Asset are jointly investing about 1.8 billion yuan to build the NOVARTIS AG.

The US Food and Drug Administration expanded the use of a NOVARTIS AG drug to treat adults with a chronic skin condition causing recurring itchy welts.

The U.S. Food and Drug Administration approved NOVARTIS AG’s Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.

Novartis acquired global rights to Abogen's ABO2203 in a $7.8 billion deal, strengthening its RNA therapeutics pipeline.

Novartis AG agreed to license an mRNA-based autoimmune therapy from China's Abogen Biosciences in a deal worth up to $7.8 billion.

The Kerala High Court ruled that the Central government may invoke Section 100 of the Patents Act to manufacture and sell patented medicines on a non-commercial basis, including when patented drugs are sold at exorbitant prices.

Novartis's RNA drug del-desiran fell short in a rare muscle disease study.

Telix Pharmaceuticals agreed to acquire all shares of privately held ITM Isotope Technologies Munich SE in a radiopharmaceuticals merger worth at least $1.65 billion, with up to $700 million more contingent on ITM's lead drug meeting regulatory and sales goals.

Novartis received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for COSENTYX for the treatment of polymyalgia rheumatica (PMR).

Nestlé Japan is expanding its nutrition food business for elderly people by broadening distribution beyond medical institutions, mainly to drugstores, and increasing flavor varieties to capture home-care demand.

Novartis halted development of its investigational ALS therapy VHB937 after the ASTRALS Phase 2 trial failed to meet its primary or secondary endpoints.

Novartis met with Ghana Medical Trust Fund and expressed willingness to support it with medical equipment, training and research collaboration, with no money committed and no agreement signed.

Novartis announced the termination of development of its ALS drug VHB937.

Legend Biotech appointed Ingrid Zhang, a Novartis executive, as CEO, ending a nearly two-month search that began when former CEO Ying Huang resigned in July.

Novartis shares slumped 11% in one day, wiping nearly $30 billion off its market value, after the failure of the muscle-wasting disorder drug del-desiran in a late-stage study.

In US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.

Whitehawk Therapeutics appointed Vijay Iyengar as a Class III director effective September 9, 2026, with an initial stock option award for 76,080 shares.

Artisan Partners, a shareholder of Novartis AG, publicly urged the Swiss drugmaker to shake up its board and overhaul its M&A approach after share declines following three clinical trial setbacks.

Palantir Technologies hosted its eleventh AIPCon event in Miami, featuring customer presentations on AI applications.

Ionis Pharmaceuticals and partner Novartis announced on Friday that their experimental heart drug failed in a late-stage trial.

Novartis announced that its experimental cardiovascular drug pelacarsen failed to reduce cardiovascular risk in the Phase 3 HORIZON trial.

Novartis plans to cease production at its Kleinhüningen site in Basel, potentially eliminating about 130 jobs, subject to information and consultation procedures.

South Korea's Alteogen signed a deal with Swiss drugmaker Novartis worth up to $3.22 billion, granting Novartis access to Alteogen's technology for making injectable versions of intravenous drugs.

Novartis announced that its oral drug remibrutinib met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.

Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.